Nick Paul Taylor

Biography for Nick Paul Taylor

Nick Taylor, UK Correspondent

Nick Taylor is a freelance journalist with more than six years' experience of reporting on the global biopharma industry. Since graduating with a biology degree from the University of York, Nick has written for numerous healthcare publications, including Nature BioPharma Dealmakers, Life Science Leader and Outsourcing-Pharma. You can contact him at and follow him on Twitter at @NickPaulTaylor.

Articles by Nick Paul Taylor

Daiichi misses H5N1 vaccine production goal after low yields slash output

The seed strain is often to blame for low yields of vaccines to protect against pandemic flu strains H1N1 and H5N1, but Daiichi Sankyo has now encountered difficulties when processing the vaccine, leaving the drugmaker unable to hit the H5N1 vaccine production target it agreed upon with the Japanese government.

Antibody discovery opens new avenue for HIV vaccine development

A team of U.S. and South African researchers has identified and cloned an antibody that targets one of the few unchanging regions of HIV.

Study: Merck's Gardasil halves risk of precancerous lesions

The success of Australia's HPV vaccination catch-up program has given the country a world-leading trove of real-world data on the effectiveness of Merck's Gardasil. By mining this database, researchers have estimated the vaccine halves the risk of young women developing high-grade cervical abnormalities.

Study: Pro-vaccine messages can intensify immunization opposition

While childhood immunization rates show the vast majority of U.S. parents support vaccination, the country is dotted with clusters of people who think the risks outweigh the benefits. Reaching the 10% who decline the measles, mumps and rubella (MMR) vaccine is a challenge for healthcare authorities and research suggests there is no easy solution.

Report: U.K. facing $100M compensation payout relating to GSK's swine flu vaccine

While Finland agreed to pay out in 2011, the U.K. was still knocking back claimants in 2012. Now, though, the U.K. government is reportedly readying to pay 60 people $1.7 million each.

CDC reports switch to 2-dose regimen of Merck's chickenpox vaccine a success

In the decade after Merck began selling its chickenpox vaccine in the U.S. the proportion of infants immunized against the virus rose to almost 90%. Yet immunized kids continued to catch chickenpox and the virus even killed two people who had received the vaccine. This week the Centers for Disease Control and Prevention reported on the success of the strategy it adopted to prevent such cases.

CDC is 'not unduly alarmed' by cases of a polio-like illness in California

While polio has been eradicated across much of the earth, other viruses from the same family continue to circulate. Many infections are mild or even asymptomatic, but occasionally the viruses can cause the paralysis associated with polio. Over the past 18 months, Stanford University researchers have identified 20 possible cases in California.

Taiwan's Adimmune targets June start for mass production of bird flu vaccine

At this stage it is unclear if the Taiwanese government would buy the vaccine. Adimmune is continuing development though so it is ready to produce the vaccine if required.

MMR vaccine linked to fall in respiratory-related hospitalizations

Some studies in low-income countries have shown that widespread immunization can cause unexpected positive consequences. A Danish team has now generated evidence that some of these unintended benefits are seen in wealthy countries, too.

Pfizer reports its huge trial of Prevnar has met its primary and secondary goals

The New York-based drugmaker is keeping the data under wraps until next month but has revealed the headline results. Primary and secondary objectives were all met.